Doxorubicin (DOX) is a well-known anti-cancer anthracycline drug that has been demonstrated to overexpress (off-target) signaling cascades PI3K/AKT, NF-κB and ERK/MAPK mainly responsible for its resistance by inhibiting apoptotic and autophagic death-related proteins- Bcl-2, caspase-3/7/8/9, p62, and LC3-I/II in the uterine and breast carcinoma [372–376]. This evidence concerns the gene BCL2 and cancer.